Antihyperlipidemic Drugs Market - Global Industry Analysis

Global Antihyperlipidemic Drugs Market: Overview

Hyperlipidemia also referred to as hyperlipoproteinemia, is a lipid condition characterized by elevated lipid (fat) levels in the blood. It's caused by a problem with lipid metabolism, a problem with plasma lipoprotein production & breakdown, or a plasma lipid transport. Hyperlipidemia is a serious medical problem that must be addressed. Lipid-lowering medications also called cholesterol-lowering, or antihyperlipidemic drugs, are a class of drugs that are used to lower high blood levels of lipids (fats) and lipoproteins (fats containing protein). These medicines are meant to treat cardiovascular disorders such as atherosclerosis and reduce the risk of heart attacks.

Report Scope:

Global Antihyperlipidemic Drugs Market: Growth Factors

The global antihyperlipidemic drugs market is fueling at a speedy rate. The prime factor contributing to the growth of the market is the rise in cases of hyperlipidemia and cardiovascular diseases. CVD is the world's leading cause of mortality. In 2019, 17.9 million individuals died from cardiovascular disease (CVD), accounting for 32% of all deaths worldwide. Heart attacks and strokes were responsible for 85 percent of these fatalities. CVD is also the biggest cause of mortality in Europe, responsible for 47 percent of women's deaths and 39 percent of men's deaths. Furthermore, according to a survey by faculty members at the University Putra Malaysia's Department of Nutrition and Health Sciences, cardiovascular diseases are anticipated to cause seven out of every ten fatalities in developing countries by 2020. This is leading to the huge demand for antihyperlipidemic drugs, thereby driving the market growth. In addition to this, an increase in sedentary lifestyle, rise in healthcare expenditure, and rise in geriatric population are also some of the key factors that are driving the global market. Furthermore, in the near future, significant research and development of antihyperlipidemic combination drugs is expected to boost the global antihyperlipidemic drugs market. However, the increased cost of therapy, as well as strict government rules and laws around medication patents, may limit the global antihyperlipidemic drugs market growth.

COVID-19 was formerly assumed to be a virus that only affected the lungs, but it has now been shown that it may also affect and damage the heart, posing a higher risk of consequences for the many individuals worldwide who already have or are at risk of heart disease. Cardiovascular problems are common in COVID-19 patients, and these, together with pre-existing cardiovascular comorbidities and RF, may lead to severe clinical outcomes and death. Clinicians all across the globe should be aware of this link in order to identify patients who are at higher risk. In the projection period, the increased prevalence of illness among CVD patients would fuel the rise of antihyperlipidemic drugs.

Global Antihyperlipidemic Drugs Market: Segmentation

The global antihyperlipidemic drugs market is bifurcated based on the route of administration, drug class, distribution channel, and region. Based on the route of administration, the global market is divided into intravenous and oral. Cholesterol absorption inhibitors, bile acid sequestrants, statins, combination, PCSK9 inhibitors, and fibric acid derivatives are the drug class of antihyperlipidemic drugs. The distribution channel segment is classified into online retailers, retail stores, and hospital pharmacies.

Global Antihyperlipidemic Drugs Market: Regional Analysis

In terms of revenue, North America is anticipated to lead the global antihyperlipidemic drugs market, and this trend is expected to continue over the projected period. The market for antihyperlipidemic drugs in North America is expected to grow as the frequency of vascular disorders and the number of amputations in the area rise. North American market expansion may also be ascribed to significant expenditures in R&D and healthcare spending by governments and commercial companies in the prosthetics industry in the area. In terms of market share for antihyperlipidemic drugs, Europe is expected to hold the second position in the market. This is owing to mandatory medical insurance in nations like France and Germany, as well as significant disposable income and considerable R&D activity in the region's healthcare industry.

Global Antihyperlipidemic Drugs Market: Competitive Players

Biotest AG, Shire Plc, Pfizer, Inc., Grifols S.A., AstraZeneca plc, Talecris Biotherapeutics, Inc, Baxalta Incorporated, Kedrion S.p.A., Octapharma AG, and Boehringer Ingelheim GmbH are the dominating players that are functioning in the global antihyperlipidemic drugs market.

Global Antihyperlipidemic Drugs Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.